标题
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
作者
关键词
-
出版物
Translational Research
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-10-30
DOI
10.1016/j.trsl.2023.10.005
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease
- (2023) Pascale Gluais Dagorn et al. KIDNEY INTERNATIONAL
- Calcium-sensing receptor activator cinacalcet for treatment of cyclic nucleotide-mediated secretory diarrheas
- (2023) Tifany Chu et al. Translational Research
- Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD
- (2022) Bart J. Kramers et al. Clinical Journal of the American Society of Nephrology
- Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
- (2022) Xiaofang Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Lubiprostone is a Non-Selective Activator of cAMP-Gated Ion Channels and Chloride Channel Protein 2 (Clc-2) Has a Minor Role in its Prosecretory Effect in Intestinal Epithelial Cells
- (2022) Apurva A. Oak et al. MOLECULAR PHARMACOLOGY
- A systematic review and meta-analysis of efficacy and safety of Calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
- (2022) Tianbiao Zhou et al. CURRENT PHARMACEUTICAL DESIGN
- Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
- (2021) Shinya Nakatani et al. Scientific Reports
- Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease
- (2021) Annarita Di Mise et al. FASEB JOURNAL
- Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
- (2021) Ioannis Bellos Therapeutics and Clinical Risk Management
- An update on the use of tolvaptan for ADPKD: Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders (WGIKD), the European Rare Kidney Disease Reference Network (ERKNet) and Polycystic Kidney Disease International (PKD-International)
- (2021) Roman-Ulrich Müller et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Does In Vitro Potency Predict Clinically Efficacious Concentrations?
- (2020) Rasmus Jansson‐Löfmark et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Targeting chloride transport in autosomal dominant polycystic kidney disease
- (2020) François Jouret et al. CELLULAR SIGNALLING
- Vitamin D and Calcimimetics in Cardiovascular Disease
- (2018) Kenneth Lim et al. SEMINARS IN NEPHROLOGY
- Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells
- (2018) Annarita Di Mise et al. Scientific Reports
- Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
- (2017) Markus Ketteler et al. KIDNEY INTERNATIONAL
- Autosomal dominant polycystic kidney disease: the changing face of clinical management
- (2015) Albert C M Ong et al. LANCET
- Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease
- (2013) Olivier Devuyst et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Cinacalcet hydrochloride for the treatment of hyperparathyroidism
- (2013) Nicolas Verheyen et al. EXPERT OPINION ON PHARMACOTHERAPY
- Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
- (2013) V. E. Torres et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Potent, Metabolically Stable Benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR Inhibitors for Polycystic Kidney Disease
- (2011) David S. Snyder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
- (2011) V. Takiar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet Hydrochloride
- (2009) Desmond Padhi et al. CLINICAL PHARMACOKINETICS
- Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD
- (2009) V. H. Gattone et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Type II Calcimimetics and Polycystic Kidney Disease: Unanswered Questions
- (2009) V. E. Torres JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1
- (2008) Sekiya Shibazaki et al. HUMAN MOLECULAR GENETICS
- Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney Disease
- (2008) B. Yang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease
- (2008) X. Wang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts
- (2008) Michael B. Hovater et al. Purinergic Signalling
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started